How Is Tysabri-Related PML Monitored and Tested?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk Management

If you or a loved one is taking Tysabri, understanding the monitoring and testing for PML is crucial. The medical community has long emphasized the importance of transitioning from broad risk awareness to precise, individualized assessment. This page covers the key tests and follow-up protocols used to evaluate PML risk in patients on Tysabri.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and, when linked to Tysabri, usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable and can mimic multiple sclerosis relapses, making diagnosis challenging. Symptoms may include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and, in some cases, seizures. Diagnosis relies on brain MRI, which may show characteristic lesions, and detection of JCV DNA in cerebrospinal fluid. A baseline MRI before starting Tysabri is recommended to help differentiate subsequent multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating and continuing therapy. The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to mitigate risk through careful patient selection and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs normal immune surveillance, allowing latent JCV to reactivate and cause PML. The risk is highest in patients with detectable anti-JCV antibodies, which indicate prior exposure to the virus. Regarding prognosis, PML associated with Tysabri carries a poor outlook. The boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Outcomes in these cases were severe, consistent with the known natural history of PML. Even with prompt diagnosis and management, many survivors experience permanent neurological deficits.

Timeline and Monitoring After Tysabri Exposure

The timeline between Tysabri exposure and PML onset can vary. Risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML has also been reported after discontinuation of Tysabri in patients who had no signs of PML at the time of stopping therapy. Therefore, monitoring for new symptoms should continue for at least six months after the last dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This delayed presentation underscores the need for prolonged vigilance. The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which is the strongest safety communication required by the FDA. The warning clearly states that Tysabri increases PML risk, lists the three major risk factors, and instructs healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML. It also mandates immediate withholding of Tysabri at the first suspicion of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to prescribers and patients who are educated about PML risks and agree to regular monitoring. Despite these measures, PML remains a devastating complication, and the prognosis for affected patients is poor.

Prognosis and Long-Term Outcome

In summary, PML is a serious adverse effect of Tysabri with a high likelihood of death or severe disability. Risk is stratified by anti-JCV antibody status, treatment duration, and prior immunosuppressant use. The onset can occur during therapy or after discontinuation, necessitating extended monitoring. While the boxed warning and restricted distribution program provide important safeguards, the long-term outcome for patients who develop PML is generally unfavorable. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for patients who develop PML after Tysabri treatment?

The long-term prognosis for PML associated with Tysabri is poor, with the boxed warning stating that it usually leads to death or severe disability. Even with prompt diagnosis and management, many survivors experience permanent neurological deficits (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How long after stopping Tysabri should patients be monitored for PML?

Monitoring for new symptoms suggestive of PML should continue for at least six months after the last dose of Tysabri, as PML has been reported after discontinuation in patients who had no signs at the time of stopping therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the three main risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.